Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Reports Q4 revenue $22.5B, consensus $22.45B. “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an ...
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Johnson & Johnson posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations ...
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the ...
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week’s Game Plan. In this article, we are ...